Cargando…

Neurologists’ Knowledge, Practice, and Attitudes towards Pharmacovigilance and Adverse Drug Reactions Reporting Process in Epileptic Patients—Comparative Analysis from Poland and Egypt

Objectives: To compare neurologists’ knowledge, practice, and barriers of pharmacovigilance (PV) process among patients with epilepsy in Poland and Egypt. Methods: It was an international study that used an online questionnaire e-mailed to neurologists registered to practice in Poland and Egypt. Res...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopciuch, Dorota, Kamal, Nashwa Nabil, Kamal, Nashaat Nabil, Hamdy, Nermin Aly, Paczkowska, Anna, Zaprutko, Tomasz, Ratajczak, Piotr, Fliciński, Jędrzej, Kus, Krzysztof, Nowakowska, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998900/
https://www.ncbi.nlm.nih.gov/pubmed/35409851
http://dx.doi.org/10.3390/ijerph19074169
Descripción
Sumario:Objectives: To compare neurologists’ knowledge, practice, and barriers of pharmacovigilance (PV) process among patients with epilepsy in Poland and Egypt. Methods: It was an international study that used an online questionnaire e-mailed to neurologists registered to practice in Poland and Egypt. Results: Most of the neurologists were familiar with the definition of PV and adverse drug reactions (ADRs), but relatively few neurologists knew where to report ADRs, especially the Egyptian neurologists. Only 31.11% of the neurologists from Egypt and 39.90% neurologists from Poland declared that they had reported ADRs at least once during their professional practice, and few of them declared the regular reporting of such incidents. The main reason for the neurologists not reporting ADRs was the lack of time and a conviction that reporting ADRs would be an additional burden that would generate extra work. Conclusion: The standards of pharmacovigilance process, safety control, and quality are not the same throughout the world. System-regulated PV stabilization in a country translates into the practice of maintaining PV. Monitoring the safety of pharmacotherapy and knowledge of risks associated with ADRs should be included in the academic curricula of physician courses.